Extending Survival of Stage IV Non-Small Cell Lung Cancer
Simona Carnio, Silvia Novello, Teresa Mele et al. · Seminars in Oncology · 2013
Cited by 40 works. doi:10.1053/j.seminoncol.2013.12.013
Authors
References
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Cancer statistics, 2012
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials